Suven Life Sciences Limited (BOM:530239)
India · Delayed Price · Currency is INR 372.40
-2.05 (-0.55%)
At close: Aug 21, 2026
Suven Life Sciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 88.14 | 71.15 | 66.56 | 116.93 | 135.39 | 118.44 |
Other Revenue | - | - | - | - | 0.56 | 1.06 |
| 88.14 | 71.15 | 66.56 | 116.93 | 135.95 | 119.51 | |
Revenue Growth | 17.26% | 6.89% | -43.08% | -13.99% | 13.76% | -15.08% |
Cost of Revenue | 6.32 | 6.32 | 7.51 | 8.24 | 5.66 | 24.33 |
Gross Profit | 81.82 | 64.83 | 59.05 | 108.69 | 130.29 | 95.18 |
Selling, General & Admin | 335.87 | 322.81 | 211.17 | 190.24 | 186.21 | 210.21 |
Research & Development | 3,305 | 2,482 | 1,440 | 1,144 | 1,154 | 1,064 |
Other Operating Expenses | 99.42 | 101.38 | 61.96 | 52.08 | 45.56 | 39.53 |
Operating Expenses | 3,805 | 2,962 | 1,771 | 1,452 | 1,451 | 1,357 |
Operating Income | -3,723 | -2,897 | -1,712 | -1,343 | -1,320 | -1,262 |
Interest Expense | -6.34 | -1.58 | -0.47 | -1.58 | -2.89 | -5.32 |
Interest & Investment Income | 42.48 | 42.48 | 56.83 | 164.25 | 64.16 | 11.26 |
Currency Exchange Gain (Loss) | -2.42 | -2.42 | -2.27 | -0.7 | -3.28 | -3.71 |
Other Non Operating Income (Expenses) | 69.32 | 0.09 | 0.62 | 0 | - | 0 |
EBT Excluding Unusual Items | -3,620 | -2,859 | -1,657 | -1,181 | -1,262 | -1,260 |
Gain (Loss) on Sale of Investments | 95.37 | 95.37 | 49.76 | 45.49 | 17.92 | 3.56 |
Asset Writedown | - | - | - | - | -0.02 | -0.86 |
Other Unusual Items | - | - | - | 0.11 | 1.85 | 0.13 |
Pretax Income | -3,524 | -2,763 | -1,607 | -1,061 | -1,183 | -1,220 |
Income Tax Expense | - | - | - | -10.02 | - | - |
Net Income | -3,524 | -2,763 | -1,607 | -1,051 | -1,183 | -1,220 |
Net Income to Common | -3,524 | -2,763 | -1,607 | -1,051 | -1,183 | -1,220 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 239 | 228 | 218 | 218 | 178 | 135 |
Shares Outstanding (Diluted) | 239 | 228 | 218 | 218 | 178 | 135 |
Shares Change | 9.53% | 4.44% | - | 22.31% | 32.29% | 5.88% |
EPS (Basic) | -14.74 | -12.13 | -7.37 | -4.82 | -6.63 | -9.05 |
EPS (Diluted) | -14.74 | -12.13 | -7.37 | -4.82 | -6.63 | -9.05 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -3,065 | -1,914 | -1,155 | -1,189 | -1,473 |
Free Cash Flow Per Share | - | -13.46 | -8.78 | -5.29 | -6.67 | -10.93 |
Dividend Per Share | - | - | - | - | - | 1.000 |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 92.83% | 91.12% | 88.71% | 92.95% | 95.84% | 79.64% |
Operating Margin | -4223.81% | -4072.38% | -2572.07% | -1148.48% | -971.27% | -1056.14% |
Profit Margin | -3998.70% | -3884.13% | -2415.11% | -898.63% | -869.95% | -1020.82% |
Free Cash Flow Margin | - | -4307.95% | -2875.39% | -987.51% | -874.42% | -1232.64% |
EBITDA | -3,671 | -2,845 | -1,659 | -1,285 | -1,262 | -1,227 |
D&A For EBITDA | 51.88 | 52.06 | 52.78 | 57.89 | 58 | 35.41 |
EBIT | -3,723 | -2,897 | -1,712 | -1,343 | -1,320 | -1,262 |
Revenue as Reported | 296.68 | 210.45 | 175.53 | 328.23 | 219.88 | 134.46 |